A 24-week, open-label phase 3 trial (termed KIWI) was performed in children with CF aged 2–5 years with at least one CFTR gating mutation to investigate IVA pharmacokinetics, safety, and efficacy [25]. The gene discussed is CFTR; the disease is cystic fibrosis.